Fig. 3From: Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle EastProportion of patients with relapses in the 12–24 and 0–12 months before baseline and during the study by treatment (FAS). DMT, disease-modifying treatment; FAS, full analysis set Back to article page